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Summary 
Male STR/ort mice develop osteoarthritis n the tibial articular cartilage. Low grade histological lesions first appear 
between 10-20 weeks of age. A previous study showed that the level of aggrecan, the major cartilage proteoglycan, 
is approximately twofold greater in the tibial cartilage of 16-19-week-old STR/ort mice compared with that in normal 
cartilage in control CBA mice. In the present investigation aggrecan gene transcription was investigated in 
20-week-old STR/ort and CBA tibial cartilage using a quantitative reverse transcription-polymerase chain reaction 
(RT-PCR). The amount of aggrecan cDNA obtained from the STR/ort medial and lateral plateau was 2.8- and 4.6-fold 
greater per milligram of wet cartilage than that from the CBA tibial plateau. The difference was not due to differences 
in cellularity of tibial cartilage in thetwo strains and indicates that aggrecan gene transcription is elevated in early 
osteoarthritis. 
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Introduction 
LITTLE is known about  the ear ly b iochemical  
events  in osteoarthr i t is .  Natura l ly -occurr ing  osteo- 
ar thr i t i s  in  an imals  provides a model for investi- 
gat ing this. The STR/ort  mouse is one model, with 
85% of all males developing histological  esions of 
osteoarthr i t i s  in the media l  t ibial  p la teau cart i lage 
from about  10 weeks of age onwards.  Lesions first 
appear  in the cart i lage ad jacent  o the insert ion of 
the anter ior  cruc iate  l igament  and subsequent ly,  
in other  parts  of the cart i lage.  The lesions closely 
resemble those found in human osteoarthr i t i s  [1]. 
Lesions are also found in the latera l  cart i lage,  
a l though they occur  less f requent ly  and are 
genera l ly  less severe at this site (Chambers  and 
Mason,  unpubl ished observat ions) .  
Prev ious  studies showed that  the level of 
chondro i t in  sul fate in both  the medial  and lateral  
t ibial  cart i lage of 16-19 weeks old STR/ort  mice is 
about  twofold greater  than  that  in age-matched 
CBA mice [2]. CBA mice rarely, if ever, develop 
osteoarthr i t i s  in the t ibial  p lateau.  Large pore gel 
e lectrophores is  and Western  b lott ing identif ied 
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aggrecan  as the major  ar t i cu lar  cart i lage proteo- 
g lycan in both stra ins of mouse,  and in normal  and 
osteoarthr i t i c  art i lage.  High levels of aggrecan  in 
ear ly osteoarthr i t i c  cart i lage could be due to 
increased t ranscr ip t ion  and synthesis of the 
proteoglycan,  or to decreased turnover ,  or to both 
mechanisms.  The smal l  size of the mouse t ibial  
p la teau cart i lage and the re lat ive ly  smal l  number  
of chondrocytes  avai lable,  together  with the h igh 
concent rat ion  of g lycosaminog lycan present,  pre- 
cludes the use of Nor thern  blots to invest igate  
aggrecan  mRNA levels in this tissue. As an 
a l ternat ive  approach,  we have  used quant i ta t ive  
reverse t ranscr ip t ion  po lymerase  chain  react ion  
(RT-PCR) to assess aggrecan  mRNA levels in t ibial  
cart i lage of STR/ort  and CBA mice. The protocol  
is based on the use of a compet i t ive in terna l  
starrdard (the mimic) which competes wi th  aggre- 
can cDNA for aggrecan  specific pr imers in the PCR 
react ion.  Any di f ferences in the amount  of 
aggrecan  cDNA obta ined f rom different cart i lages 
by RT-PCR of the i r  mRNA could be due to 
di f ferences in cart i lage cell density, as well  as to 
dif ferent levels of aggrecan  mRNA in the cells. The 
mouse t ibiat car t i lage does not  conta in  suff ic ient 
cel lu lar  DNA to be measured  by convent iona l  
DNA assays. Thus we assessed the DNA content  of 
these cart i lages us ing a method based on probe 
hybr id izat ion to mouse major  satel l i te DNA [3]. 
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Mater ia l s  and  Methods  
ISOLATION OF mRNA 
Full-thickness medial and lateral tibial articu- 
lar cartilage was dissected from the hind legs of 
nine 20-week-old STR/ort mice and six 20-week- 
old male CBA mice, and weighed as described 
previously [2]. Total RNA was prepared directly 
from mouse cartilage without prior homogeniz- 
ation, using RNAzol  B as described in the 
manufacturer's instructions for small tissue 
samples (AMS Biotechnology U.K. Ltd.). Briefly, 
individual cartilage samples were extracted di- 
rectly with 0.8 ml RNAzol B reagent. No cartilage 
residue was visible after this step, indicating 
complete solubilization of the tissue. After adding 
80pl chloroform the samples were stored for 
5min at 4°C with constant mixing and then 
centrifuged for 5 min at room temperature. The 
aqueous phase was collected and precipitated 
overnight with 0.4 ml isopropanol at -20°C. The 
samples were then washed once with 75% ethanol 
and re-precipitated with two volumes of absolute 
alcohol in the presence of 0.2 M NaC1 for 1 h at 
-20°C. The RNA was pelleted by centrifugation at
11 600 g for 10 min, washed with 200 pl of absolute 
ethanol and air dried at room temperature for 
10min. Each sample was made up in 10p] 
DEPC-treated water, kept at -20°C, and used for 
RT within 2 h. 
RT 
Mouse mRNA was reverse transcribed to cDNA 
with random hexamer primers (Pharmacia, U.K.) 
and the Super Script II RNase H- reverse 
transcriptase enzyme (Gibco BRL), using the buffer 
system provided by the manufacturers. Each RNA 
sample in 10 pl DEPC-treated water was incubated 
at 65°C for 5min to denature its secondary 
structure and then placed on ice for 5-10 min. After 
brief centrifugation, samples were added to fresh 
0.5 ml pre-labeled Eppendorf tubes containing 6 ~1 
of 5 x concentrated first strand buffer [250 mM Tris 
(HC1 (pH 8 at room temperature), 375 mM KC1, 
15 mM MgC12], 3 ~1 of 0.1 M dithiothreitol, 6 ~1 of a 
2.5 mM mixed dNTP stock solution (Gene Amp 
dNTPs, Perkin Elmer), 0.5 pl RNAguard RNase 
inhibitor (34 200 units/ml; Pharmacia U.K.), 2.5 ~L1 
DEPC-treated water, 1 pl of 100 ~tM random 
haxamers and 1 pl (200 units) Super Script II 
enzyme. Samples were incubated at 37°C for 1 h 
and the resultant cDNAs precipitated with two 
volumes of ethanol and 0.1 volume of 3 M sodium 
acetate, overnight, at -20°C.  After centrifuging 
(11 600g, 10 min) the supernatants were removed 
and the cDNA pellets were washed once with 100 ~l 
of 70% ethanol to remove the salt. After air drying 
at room temperature for 10 min, each sample was 
solubilized in 10 pl DEPC-treated water and stored 
at -20°C. 
PCR 
Gene specific primers for mouse aggrecan were 
designed to amplify a 191 bp fragment in the 
linking region between the Ig fold and the first 
tandem repeat. The primers were designed using 
the published sequence for murine aggrecan [4] 
and were as follows: Sense5' ACC CTG GAC TTT 
GAT CGA GC 3' (nucleotide 626-645) and Anti- 
sense 5' GGG AAC TCG TCC TTG TCA CC 3' 
(nucleotide 797-816). 
Taq DNA polymerase used to amplify the cDNA 
samples, and its buffer, were obtained from Gibco 
BRL. Templates were first heat denatured at 94°C 
for 5 min and then placed on ice for 5-10 min to 
prevent re-annealing of single stranded DNA. 
After a brief centrifugation, 10 ~l of each cDNA 
was added to an Eppendorf tube containing 5pl of 
xl0 PCR buffer (200 mM Tris HC1, pH 8.4, 500 mM 
KC1), 4 pl of the same 2.5 mM dNTP mix as used in 
the RT, 1.5 ~tl of 50 mM MgC1, 1.25'pl of each primer 
(sense and antisense at 20 ng/~tl), 26.75 ~tl DEPC- 
treated water and 0.25 pl Taq DNA polymerase 
(5 U/~l). After mixing and a brief centrifugation, 
50 pl mineral oil was layered over the reaction 
mixture. Samples were subject to 30 cycles of 
denaturation at 94°C for 1 min, annealing at 50°C 
for 1 min, extension at 72°C for 1 rain followed by 
10rain post-extension at 72°C, using a Hybaid 
Omnigene thermocycler. The appropriate PCR 
products were validated by restriction enzyme 
digestion with PST1 and by DNA sequencing. 
QUANTITATIVE PCR 
An aggreca n mimic consisting of a nonhomo- 
logous sequence flanked by aggrecan gene specific 
sequences at each end was constructed with the aid 
of a kit (Clontech, PCR Mimic Construction Kit). 
Known concentrations of the mimic were included 
in PCR reactions to amplify aggrecan cDNA and 
acted as a competitor for aggrecan specific 
primers. The nonhomologous sequence supplied 
was a 580 bp BamHI/EcoRI restriction fragment of 
V-erbB. The size of the mimic was determined by 
choosing an appropriate target sequence in this 
neutral DNA fragment and amplifying it by PCR 
using the composite primers shown below: 
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Sense 
Ant isense 
Aggrecan  specific pr imer  
sequence 
20-base pair  sequence which 
annea ls  to the neutra l  DNA 
I I I 
5' ACCCTGGACTTTGATCGAGCCAAGTTTCGTGAGCTGATTG 3' 
5' GGGAACTCGTCCTTGTCACCCAGAATTGTTGCTAGTAGCG 3' 
This produced a 300 bp neutra l  DNA f ragment  
f lanked by the aggrecan  specific sequences.  A 
second round of PCR us ing the aggrecan  specific 
pr imers  only was then used to ampl i fy  the final 
mimic DNA. 
A f te r  puri f icat ion,  the PCR mimic was elec- 
t rophoresed on an agarose  gel, together  with a 
series of di lut ions of the DNA size markers  suppl ied 
with the Clontech mimic const ruct ion  kit. The 
mimic was quanti f ied by compar ing  its band 
intens i ty  with those of the markers .  The mimic 
DNA was co-amplif ied with mouse aggrecan  cDNA 
obta ined by RT of cart i lage mRNA. For  each 
exper iment,  10 quant i ta t ive -PCR react ions  were set 
up. Each conta ined mimic DNA at doubl ing 
di lut ions (0.8-0.05 or 0.4-0.025 attomoles/ tube)  and 
constant  amounts  of the ta rget  cDNA derived from 
the latera l  or medial  t ibial  ar t icu lar  cart i lage.  A 
contro l  react ion  was a lways per formed omit t ing 
the target  and mimic DNA. The PCR condit ions 
were ident ical  to those descr ibed above except hat  
the react ion  mix conta ined 2 gl mimic di lut ion or 
di luent only and the vo lume of water  was reduced 
to 24.75pl. The PCR products  were separated 
e lectrophoret ica l ly  on an agarose gel conta in ing 
0.5 gg/ml eth id ium bromide (Fig. 1). UV- i r rad iated 
gels were photographed,  and the negat ives canned 
with a laser densitometer.  Because the mimic was 
1.57 x larger  than. the aggrecan  PCR fragment,  the 
Lane 1 2 3 4 5 6 
indiv idual  f luorescence values obta ined for the 
mimic were divided by this factor  before the rat io  of 
ta rget  to mimic was calculated.  The data, expressed 
as a rb i t ra ry  opt ical  density units, were p lot ted as 
shown in Fig. 2. The data on the x-axis shows the 
number  of at tomoles  of a mimic DNA p lot ted as a 
reciprocal .  In  most  graphs,  the max imum rat io  of 
target:  mimic cDNA was 2 or greater  (Fig. 2). The 
concent ra t ion  of aggrecan  cDNA in at tomoles  was 
taken  f rom the in tercept  on the x~axis where  the 
rat io  of target  to mimic  was 1:1. 
DNA QUANTITATION 
Separate  DNA isolat ions were made from the 
t ibial  a r t i cu lar  car t i lage of six 20-week-old male 
STR/ort  mice and from six CBA contro l  mice using 
the Tr iso lv  iso lat ion reagent  (Biotex Laborator ies  
Inc., Houston,  TX, U.S.A.), accord ing to the 
manufacturer ' s  instruct ions.  Car t i lage wet 
weights were obta ined as descr ibed above. Mouse 
DNA was quant i ta ted  us ing the method of Walsh  
et al. [3]. DNA for use as a s tandard  was iso lated 
from mouse liver. After  quant i f icat ion of the l iver 
DNA by spect rophotometry ,  serial  d i lut ions were 
made over  a work ing  range of 0.02 0.5 ng/100 pl 
buffer. Mouse cart i lage DNA or s tandards  were 
slot b lotted onto posi t ively charged ny lon mem- 
branes (Hybond N +, Amersham In ternat iona l  plc) 
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FIG. 1. Quantitative RT-PCR measurement of aggrecan mRNA extracted from the tibial cartilage of a 20-week-old 
STR/ort mouse. The target, aggrecan cDNA (191 bp), and a mimic DNA (300 bp) were co-amplified by PCR and separated 
by agarose gel electrophoresis. At the start of the PCR, each reaction contained ifferent amounts of mimic DNA, and 
constant amounts of target cDNA derived from RT of mouse tibial cartilage mRNA. Lanes 1-5, lateral cartilage; lanes 
6-10, medial cartilage. The amounts of mimic cDNA were: lanes 1 and 6, 0.8 attomoles; 2 and 7, 0.4 attomoles; 3 and 
8, 0.2 attomoles; 4 and 9 0.1 attomoles; 5 and 10, 0.05 attomoles. Lane 11 is a control PCR (no target or mimic DNA 
added). Lane 12, DNA size markers. 
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FIG. 2. Plot of the ratio of target cDNA: mimic DNA 
against known amounts of mimic DNA. The data were 
obtained by densitometry of a negative made from an 
ethidium stained gel similar to that shown in Fig. 1. ([~), 
Lateral tibial cartilage; (O), medial tibial cartilage. 
Table I. 
Mouse tibial cartilage aggrecan mRNA measured as 
cDNA after reverse transcription and quantitative'~PCR 
Aggrecan cDNA (attomoles _+ SEM) 
Mouse Lateral Medial 
strain cartilage cartilage P value 
STR/ort 0.724 i 0.114 0.606 i 01153 0.451 
CBA 0.263 i 0.070 0.133 i 0.034 0.092 
RNA was extracted from the whole lateral and medial 
tibia] plateau cartilage of 20-week-old male mice. The 
RNA was reverse transcribed and subjected to quantitat- 
ive PCR to amplify aggrecan ~DNA, as described in the 
text. The data show the mean aggrecan cDNA 
levels _+ SEM obtained from PCR amplifications ofmRNA 
from the tibial cartilages of the left and right legs of six 
CBA mice and nine STR/ort mice. Nine CBA and 14 
STR/ort joints were analysed. Statistical comparisons 
between medial and lateral plateau data for each strain 
were made using Student's t-test for paired data. No 
significant differences were found. 
and hybridized to a biot inylated probe specific for 
mouse major satell ite DNA [5, 6]. The bound probe 
was conjugated to st reptav id in-horseradish per- 
oxidase (Perkin Elmer) and detected by enhanced 
chemiluminescence (ECL detect ion system; Amer- 
sham Internat iona l  plc). Slot blot intensit ies were 
measured  by scanning the film with a dens±- 
tometer. The DNA concentrat ion of the unknowns 
was read off from a cal ibrat ion curve generated 
from the di luted mouse DNA standards. 
Statist ical  analyses were carr ied out using 
Student 's  t4est  for paired and unpaired data, as 
appropriate.  A P-value of 0.05 or less was taken as 
represent ing a statist ical ly signif icant difference 
between two sets of data. 
Resu l ts  
The amount  of  aggrecan cDNA obtained from 
the whole medial and lateral t ibial cart i lages of 
20-week-old STR/ort mice and CBA mice was 
measured after RT and quant i tat ive PCR. No 
statist ical ly-signif icant differences were found for 
aggrecan cDNA derived from the two sides of the 
joint in each strain (Table I). However,  much lower 
amounts of aggrecan cDNA were obtained from the 
tibial cart i lages of CBA mice than from STR/ort 
mice. 
At 16-25 weeks STR/ort male mice are about 
7-10 g heavier  than CBA mice and their tibial 
cart i lage wet weights are, on average, 1.4 t imes 
greater ~han those of the CBA strain. However, 
this difference in cart i lage size does not account  
for the greater  amounts of aggrecan mRNA in 
STR/ort tibial carti lages. When the data in Table I 
are expressed per mil l igrams of wet carti lage, the 
amount  of aggrecan cDNA derived from the lateral 
and medial tibial cart i lage of the STR/ort mice is 
2.8 and 4.6 times greater, respectively, than that  
from the CBA mice (Fig. 3). ~hese differences are 
signif icant (P= 0.007 and 0.024, respectively). The 
power of the analyses was 70% or better. 
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FIG. 3. Mouse tibial cartilage aggrecan mRNA measured 
as cDNA per mg of tissue, cDNA was derived from the 
lateral and medial tibial articular cartilages of nine 
20-week-old male STR/ort mice (D) and six age- and 
sex-matched CBA mice (i~) as described in Table I. Data 
ar e expressed as the mean cDNA/mg wet wt. of cartilage 
ASEM. Differences between means for the two strains 
were assessed using Student's unpaired t-test. Asterisks 
denote significant differences between STR/ort and CBA 
• mice. *P = 0.024, **P = 0.007. 
Osteoarthrit is and Cartilage Vol. 5 No. 4 23l 
7 
~ 5 
4 
~0 
3 
:~ 2 
CBA STR 
FIG. 4. DNA content of mouse tibial cartilage. DNA was 
measured in the lateral (B) and medial ([]) tibial 
cartilages of six 20-week-old male STR/ort mice and six 
age- and sex-matched CBA mice. Data are expressed as 
the mean _+ SEM/mg wet wt. of cartilage for 10-11 
replicate measurements. There were no significant 
differences between the DNA content of the medial and 
lateral cartilage, either within, or between mouse 
strains, using Student's unpaired t-test. 
We have never observed cloning of chondrocytes 
in the tibial cart i lage of 20-week-old STR/ort  male 
mice (Chambers and Mason, unpubl ished work). 
Nevertheless,  a general  increase in the number  of 
chondrocytes per mil l igram cart i lage could, con- 
ceivably, account  for the higher mRNA levels in 
the tibial p lateau of these mice. To test this, we 
measured the DNA content  of the lateral  and 
medial t ibial cart i lages of 20-week-old STR/ort  and 
CBA mice. No statist ical ly-signif icant differences 
in mean DNA .content were found between the 
strains, a l though there was considerable var iat ion 
between measurements  for individual mice of each 
strain (Fig. 4). There were no signif icant differ- 
ences in the mean DNA/mg wet cart i lage between 
the lateral  and. medial sides of the jo int  in each 
strain. Moreover,  no obvious differences in cell 
density of the cart i lage of the two strains were 
detected on histological  examinat ion of serial 
sections across the knee jo int  (Chambers and 
Mason, unpubl ished work). Thus the overal l  
chondrocyte density in tibial cart i lages of the 
STR/ort  and CBA mice is similar, and it seems 
unl ikely that  cell number  could account  for the 
h igher  aggrecan mRNA level in the STR strain. 
When the amount  of aggrecan cDNA derived from 
the tibial cart i lage of the two strains was 
expressed on the basis of t issue mean DNA 
content,  levels were signif icantly h igher  in 
STR/ort  mice compared with those in CBA mice 
(Fig. 5). 
Discuss ion  
The large proteoglycan aggrecan is t rapped 
with in a scaffold of type II col lagen fibres in the 
extracel lu lar  matr ix  of ar t icu lar  cart i lage,  an 
ar rangement  which is essential  for the t issue's 
physiological  funct ion of absorbing load. Matr ix  
synthesis and turnover  are perturbed in osteo- 
arthrit is.  Exper imenta l ly  induced osteoarthr i t i s  in 
animals has been used to invest igate such changes, 
and these studies show that  the synthesis of both 
col lagen [7, 8] and proteoglycan [9, 10] is e levated 
in vivo and in explanted cart i lage cu l tured in vitro. 
More recently,  it was observed that  mRNAs for 
aggrecan and type II col lagen are increased two- 
and eightfold, respectively,  in the ar t icu lar  
cart i lage of dogs after sect ioning the i r  anter io r  
cruc iate l igaments 10-weeks previously [11]. This 
procedure leads to the development of osteoar- 
thrit is in the knee jo int  of the animals. In another  
model in which the knee jo int  of rabbits  is 
destabi l ized by part ia l  medial  menisectomy, the 
mRNAs for the prometal loproteinases,  p roMMP1 
(c011agenase) and proMMP3 (stromelysin) are 
increased 8 weeks after the procedure [12]. 
It is noteworthy  that  when art icu lar  cart i lage 
from dogs with exper imental ly- induced osteo- 
arthr i t is  is mainta ined in explant culture,  the 
enhanced rate of synthesis of proteoglycans that  
occurs in vivo is mainta ined for a short  t ime 
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FIG. 5. Mouse cartilage aggrecan mRNA, measured as 
cDNA, plotted against cartilage cellular DNA content. 
The aggreca~:~DNA derived from the lateral and medial 
cartilages of the STR/ort (D) and CBA ([]) mice shown 
in Fig. 3 was normalized with respect to the mean 
cartilage DNA content (see Fig. 4). Differences were 
assessed using Student's unpaired t-test, Asterisks 
denote significant differences between STR/ort and CBA 
mice. *P--0.02, **P=0.004. 
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in vitro, but returns to normal evels after 48-72 h 
[13]. It is likely that the repertoire of cytokine, 
growth factor and mechanical signals, which the 
cartilage chondrocytes experience in vivo in early 
osteoarthritis, is not reproduced in vitro. Thus 
such experiments indicate that in vivo animal 
studies are necessary to establish the molecular 
mechanisms that lead to articular cartilage 
degeneration. Whilst surgically-induced animal 
models of osteoarthritis have been useful in this 
respect, there is a need to study naturally-occur- 
ring osteoarthritis in animals. Naturally-occurring 
disease develops over a period of time, as occurs 
generally in man, and changes occurring in the 
cartilage must be those due to the disease. In 
operative models, surgical trauma, bleeding and 
inflammation after the procedure may influence 
subsequent events in the joint. 
The male STR/ort mouse develops a natural 
osteoarthritis of the knee joint [1]. In our colony 
the initial histological lesions of the disease 
usually occur in the medial tibial plateau between 
10-20 weeks of age. Small areas of surface 
roughening or erosion develop in the articular 
cartilage adjacent o the tibial insertion of the 
anterior cruciate ligament. Other areas of the 
medial cartilage have a normal histological 
appearance at this stage. The lateral plateau 
cartilage is infrequently affected by lesions. We 
reported previously that the aggrecan content of 
the tibial cartilage of 16 19-week-old STR/ort 
males is markedly elevated compared with that in 
CBA and other strains of mice [2]. Both the lateral 
and medial tibial cartilages howed this elevation, 
whilst at later ages, when more advanced and 
widespread histological lesions begin to appear, 
the aggrecan level decreases. Increased eposition 
of aggrecan in the cartilage matrix during the 
early stage of developing osteoarthritis could 
occur by a number of mechanisms including 
increased transcription of the aggrecan gene, 
increased aggrecan mRNA stability or decreased 
turnover of the proteoglycan i the extracellular 
matrix. In the steady state, both increased 
transcription and increased stability of the mRNA 
would be expected to produce an expanded mRNA 
pool for aggrecan and the purpose of the present 
experiments was to test whether this occurs in the 
STR/ort mice relative to CBA mice of the same age. 
Because the size of mouse tibial cartilage is too 
small to yield enough mRNA for Northern analysis 
we used RT and quantitative PCR amplification to 
derive cDNAs representative of the aggrecan 
mRNA pool in each medial and lateral tibial 
cartilage. Our data showed that the aggrecan 
mRNA pool in early osteoarthritis n the STR/ort 
cartilage is ~ 2-4 times higher than in CBA mice 
of the same age. The higher aggrecan mRNA level 
in STR/ort mice is not due to a higher cell density 
in their cartilage because the total DNA content 
per unit weight of cartilage is the same for both 
strains. Histological examination shows no evi- 
dence of increased cell density or of cell cloning in 
20-week-old STR/ort mice. 
The aggrecan mRNA level, like the proteogtycan 
itself, is increased in both the medial and lateral 
cartilages in the STR/ort mice in comparison with 
the nonosteoarthritic CBA'Strain. Osteoarthritic 
lesions develop in the me~lial cartilage in about 
85% of the mice, but much less frequently in the 
lateral cartilage. This suggests that, in addition to 
changes in the cartilage matrix biochemistry, 
another factor is required to provoke the break- 
down of cartilage structure and the development of
histological esions of osteoarthritis. One possi- 
bility is that the medial cartilage experiences 
different mechanical loading to the lateral carti- 
lage. 
The present results indicate that the high 
deposition of aggrecan in the STR/ort tibial 
cartilage in the early stage of osteoarthritis i
associated with an enlarged mRNA pool for the 
proteoglycan, from which increased synthesis of its 
core protein could occur. The data do not enable 
us to say whether the enlarged pool is due to 
increased gene transcription, or to increased 
mRNA stability, although the first mechanism 
seems more likely. Curtis et al. [14] studied the half 
life of the aggrecan mRNA pool in explant cultures 
of bovine articular cartilage in the presence or 
absence of serum or insulin-like growth factor-1 
(IGF-1). Both serum and IGF-1 stimulated proteo- 
glycan synthesis but only serum did so by bringing 
about an increase in the aggrecan mRNA pool. 
Nevertheless, the half life of the aggrecan mRNA 
was about 4 h under all conditions of culture, 
showing that increased gene transcription rather 
than increased mRNA stability occurred in the 
presence of serum. 
A number of factors are known to modulate 
aggrecan synthesis in cartilage, and it is generally 
assumed that they do this by bringing about 
changes in transcription factors acting on the 
aggrecan gene promoter. The murine aggrecan 
promoter has been sequenced and contains everal 
consensus binding motifs for transcription factors 
including Sp-1 and the glucocorticoid receptor [15]. 
Finally, the results reported above are the first 
to show quantitative changes in the aggrecan 
mRNA pool extracted directly from articular 
cartilage in the initial stages of a natural ly 
Occurring form of the disease. 
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